key: cord-0827362-q2hj6fus
authors: Sukkar, Samir Giuseppe; Bassetti, Matteo
title: INDUCTION OF KETOSIS AS A POTENTIAL THERAPEUTIC OPTION TO LIMIT HYPERGLYCEMIA AND PREVENT CYTOKINE STORM IN COVID-19
date: 2020-08-10
journal: Nutrition
DOI: 10.1016/j.nut.2020.110967
sha: 34e43e74b62f7d4acb91e17219879373b3993b3b
doc_id: 827362
cord_uid: q2hj6fus

The severe form of Coronavirus Disease 19 (COVID-19) is characterized by "cytokine storm syndrome" (CSS) and disseminated intravascular coagulation (DIC). Diabetes, obesity and hypertension have, as minor common denominators, chronic low-grade inflammation and high plasma myeloperoxidase levels, which could be linked to pulmonary phagocytic hyperactivation and CSS. The hyperactivation of M1 macrophages with a proinflammatory phenotype, which is linked to aerobic glycolysis, leads to the recruitment of monocytes, neutrophils and platelets from circulating blood and plays a crucial role in thrombo-inflammation (as recently demonstrated in COVID- 19) through the formation of neutrophil extracellular traps (NETs) and monocyte-platelet aggregates, which could be responsible for disseminated intravascular coagulation (DIC). The modulation of glucose availability for activated M1 macrophages by means of a eucaloric ketogenic diet (EKD) could represent a possible metabolic tool for reducing ATP production from aerobic glycolysis in the M1 macrophage phenotype during the exudative phase. This approach could reduce the overproduction of cytokines and, consequently, the accumulation of neutrophils, monocytes and platelets from the blood. Second, a EKD could be advantageous for the metabolism of anti-inflammatory M2 macrophages because these cells predominantly express OXPHOS enzymes and are best fed by the oxidation of fatty acids in the mitochondria. A EKD could guarantee the availability of free fatty acids, which are an optimal fuel supply for these cells. Third, a EKD, which could reduce high lactate formation by macrophages due to glycolysis, could favor the production of interferons type I (IFNs I), which are inhibited by excessive lactate production. From a practical point of view, the hypothesis, in addition to being proven in clinical studies, must obviously take into account the contraindications of a EKD, particularly type I diabetes and type II diabetes treated with drugs that can cause hypoglycemia, to avoid the risk of side effects of the diet.

The severe form of Coronavirus Disease 19 is characterized by "cytokine storm syndrome" (CSS) and disseminated intravascular coagulation (DIC). Diabetes, obesity and hypertension have, as minor common denominators, chronic low-grade inflammation and high plasma myeloperoxidase levels, which could be linked to pulmonary phagocytic hyperactivation and CSS. The hyperactivation of M1 macrophages with a proinflammatory phenotype , which is linked to aerobic glycolysis, leads to the recruitment of monocytes, neutrophils and platelets from circulating blood and plays a crucial role in thrombo-inflammation (as recently demonstrated in through the formation of neutrophil extracellular traps (NETs) and monocyte-platelet aggregates, which could be responsible for disseminated intravascular coagulation (DIC). The modulation of glucose availability for activated M1 macrophages by means of a eucaloric ketogenic diet (EKD) could represent a possible metabolic tool for reducing ATP production from aerobic glycolysis in the M1 macrophage phenotype during the exudative phase. This approach could reduce the overproduction of cytokines and, consequently, the accumulation of neutrophils, monocytes and platelets from the blood. Second, a EKD could be advantageous for the metabolism of anti-inflammatory M2 macrophages because these cells predominantly express OXPHOS enzymes and are best fed by the oxidation of fatty acids in the mitochondria. A EKD could guarantee the availability of free fatty acids, which are an optimal fuel supply for these cells. Third, a EKD, which could reduce high lactate formation by macrophages due to glycolysis, could favor the production of interferons type I (IFNs I), which are inhibited by excessive lactate production. From a practical point of view, the hypothesis, in addition to being proven in clinical studies, must obviously take into account the contraindications of a EKD, particularly type I diabetes and type II diabetes treated with drugs that can cause hypoglycemia, to avoid the risk of side effects of the diet. macrophages into the site of inflammation, recruiting monocytes from the blood by means of monocyte chemoattractant protein (MCP) and driving them toward the M1 phenotype. 10 At the end of the process, the M1 phenotype shifts to the M2 phenotype, which eliminates apoptotic cells, debris, and pathogens. These resident macrophages represent the frontline against viruses and release powerful inflammatory mediators, such as IL-1, IL-6 and IL-18. 10 M1 chemokines (i.e., macrophage inflammatory protein-2 (MIP-2) and interleukin (IL-8)) attract neutrophils from the circulating blood to the alveolar space. As previously reported, the infiltration of neutrophils and the excessive accumulation of inflammatory cytokines are important factors that cause tissue damage due to pro-inflammatory cytotoxic mediators in ARDS. 10, 15 In addition, in acute pulmonary lesions of ARDS, platelets and neutrophils are observed and play crucial roles in thrombo-inflammation (as recently suggested in COVID-19), forming neutrophil extracellular traps (NETs) and monocyte-platelet aggregates that could be responsible for DIC. 2, 15 Therefore, in the exudative phase, a possible depletion of activated M1 macrophages could reduce neutrophil-induced alveolitis by reducing inflammatory stimulation; however, this is difficult to achieve outside of experimental models. 10, 15 A possible clinical solution that reduces the activity of M1 macrophages in the early stages of inflammation could be to target their metabolic specificity. [9] [10] 15 From a metabolic point of view, activation of the M1 phenotype induces a metabolic shift in adenosine triphosphate (ATP) production from OXPHOS to aerobic glycolysis (Warburg-like effect) ( Figure 1 ). [9] [10] The activity of the tricarboxylic acid (TCA) cycle is reduced while lactate production is increased in the presence of hypoxia, glucose overload or both. 6, 16 After the activation of hypoxia-inducible factors (HIFs), ATII cells employs exclusively glycolysis throughout changes in epigenomic and metabolomic signaling pathways. 6, 16 Zhang et al. demonstrated that under conditions of glucose overload and high lactate production, the binding of mitochondrial antiviral signaling (MAVS) to lactate in ATII cells interrupts MAVS/mitochondria localization and consequently reduces innate immune type I interferons (IFNs I) production; these phenomena play vital roles in host defense against viruses. 17 This fact could explain why a weaker IFNs response was generated by SARS than by traditional IFNs-inducing viruses. 18 

We hypothesize that a eucaloric ketogenic diet (EKD), reducing the dietetic oral supply of glucose, could favor the anti-inflammatory process through the modulation of immune metabolism. The metabolic modulation induced by a ketogenic diet can affect the following 4 targets: inhibition of M1 macrophages, activation of M2 macrophages, disinhibition of the IFNs I production induced by the overproduction of lactate, and decreased virus synthesis in cells. The reduction of glucose uptake by M1 macrophages represents the main target of the metabolic treatment of CSS because aerobic glycolysis is the main way by which ATP is produced in activated M1 macrophages and enables M1 macrophages to carry out effector functions, such as inflammatory cytokine production. 19 ( Figure 2 ). Second, a EKD could be advantageous for the metabolism of anti-inflammatory M2 macrophages metabolism because these cells are best fed by the oxidation of fatty acids in the mitochondria. 9,10 . These anti-inflammatory cells, which are derived from M1 cells, appear in the rehabilitation phase of ALI/ARDS and limit proinflammatory cytokines in the alveolar space through the production of anti-inflammatory cytokines (IL-10 and IL-1). 9,15 M2 macrophages predominantly expresses OXPHOS enzymes, and for this reason, a EKD could guarantee the availability of free fatty acids, which are an optimal fuel supply for these cells. Third, since the modulation of the glucose load could reduce the production of lactate, there would be a better production of IFN I, which is inhibited by the excessive production of lactate. 17 A final metabolic hypothesis in the treatment of COVID-19 emerges from a recent in vitro study of the proteomics of host cells infected with SARS-CoV-2, which aimed to detect potential therapeutic targets. Recently, Bojkova et al. observed that by targeting glycolysis with the desoxy-D-glucose glycolysis inhibitor (2-DG), an exokinase inhibitor that is effective against other cultivated viruses, the replication of COVID-19 in Caco-2 cells was inhibited. 20 Since agents that reduce activity of glycolysis could be potential therapeutic agents for the treatment of COVID-19 20 , a similar antiglycolytic effect could be obtained by means of ketogenic diets.

A summary of the hypothesis is provided in table 1. In obese patients affected by COVID-19, a low-calorie ketogenic diet could also be used, considering the various dietary therapeutic models described in the literature. 21 The term "ketogenic diet (KDs)" describes a variety of diets of varying composition that are rich in fat, very low in carbohydrates, and are classically composed of a 4:1 macronutrient ratio of fat-protein (which varies according to the desired caloric intake) and carbohydrates below 30 g/day. 21 While low-calorie ketogenic diets and very low-calorie ketogenic diets are used mainly in the treatment of obesity, eucaloric ketogenic diets are clinically used in the treatment of refractory epilepsy but may also have therapeutic effects in the treatment of gliomas and other diseases. [21] [22] [23] Many of these diseases present underlying metabolic diseases and chronic inflammation that have been linked to a state of hyperglycemia. [24] [25] [26] [27] [28] [29] [30] 

There is a consensus that ketosis protects healthy tissues against oxidative stress by simultaneously decreasing ROS production and increasing endogenous antioxidant capacity, even if hypoxia has metabolic effects similar to those of hyperglycemia such that reducing hyperglycemia might not cause substantial metabolic shifts. [27] [28] [29] A ketogenic diet minimizes spikes in blood glucose, reduces oxidative stress in mice 29 and reduces circulating inflammatory markers in humans. 30 A ketogenic diet, increasing the levels of hydroxybutyrate (HB), is capable of activating hydroxycarboxylic acid receptor 2 (HCA2), which is a G-protein-coupled receptor that inhibits NF-kB in macrophages, dendritic cells and microglia and reduces neuroinflammation. [31] [32] [33] In preclinical studies in mice, a ketogenic diet provoked an expansion of  T cells in the lung, improving barrier functions and antiviral resistance against influenza A virus (IAV). 34 KDs are associated with improvement in respiratory function in obese patients. [35] [36] After ten days of a very low calorie ketogenic diet (VLCKD), statistically significant improvements in the functional residual capacity (FRC) and expiratory reserve volume (ERV) were observed. 35 In addition, a 20-day VLCKD shows a significant decrease in end-tidal carbon dioxide tension (PETCO2). 36 Carbohydrate restriction represents the most important tool in diabetes management 37 , and KDs offer further benefits. 23 In intensive care units, there is a close relationship between glycemia upon admission and mortality, not only in patients with type II diabetes but also in patients without a history of diabetes mellitus (in which the form is U-shaped). 38 According to the literature, hyperlipidic diets, even if not ketogenic, could be beneficial in ICU patients undergoing artificial ventilation [39] [40] , and they could even improve respiratory failure. 41 

Before ketosis occurs, glucose may be released during the first 12 hours from glycogen reserves and from 24 to 72 hours by gluconeogenesis (from gluconeogenetic amino acids); thus, the effect of the diet can only be observed starting after 72 hours, when glycerol becomes the main substrate for gluconeogenesis. According to this consideration, it might be more beneficial to start the treatment at the onset of symptoms, which could represent a limitation to the efficacy of the treatment, even if a low intake of glucose could also be beneficial. A second limitation is that hypoxia has effects on redox potential that could be increased by ketogenic diet. The lack of glucose could lead to an insufficient NADPH/NADP+ ratio necessary to counteract the acute oxidative challenge (rapid enzymatic reduction of glutathione and other oxidized thiols), biosynthesis and/or superoxide generation during immune responses or as physiological redox signalling. 42 Oxidative pentose phosphate pathway (PPP), however, remains active under conditions of limited glucose intake because it is a thermodynamically more favourable process than glycolysis. 42 The reactions of the TCA cycle can be effectively maintained in the limited glucose supply by the oxidation of fats and amino acids and the minimum glucose content is redirected to the PPP to maintain the redox balance in the cells. 42 The KDs, besides, restore the physiological redox signaling by means of the β-hydroxybutyrate ketone contributing to the protection against oxidative stress by decreasing the production of reactive mitochondrial oxygen species. 43 Another limitation could be the possible difficulty in the use of EKD due to contraindications, in particular in some diabetic patients in whom a ketogenic diet is not indicated (table 2) . EKD can be implemented in diabetic patients with great care, and many hypothetical contraindications have been discredited. In this regard, Bruci et al. recently demonstrated that KDs have no detrimental effects on the kidney in mild renal failure 44 , and good evidence is available regarding liver safety as well. 20 A recent report by Li J et al suggests that COVID-19 infection may cause ketosis and ketoacidosis, which are correlated with a longer median length of hospital stay and a higher mortality rate. 45 Ketosis is a physiological process that is observed after prolonged fasting, and ketonuria and ketonemia are detectable after at least 1 day of fasting. [46] [47] Ketone bodies increase under conditions of fasting, starvation, and low carbohydrate diets (i.e., ketogenic diet), intense exercise and uncompensated diabetes mellitus. 48 The study does not report any information regarding nutritional status, spontaneous oral food and water intake or artificial nutritional support (parenteral or enteral nutrition), which are fundamental for verifying any relationship among ketosis, COVID-19 infection and clinical outcomes.

Patients with ketosis were probably in worse clinical conditions and were probably fasting because 21.4% of patients with ketosis vs 6.7% of patients without ketosis (p< 0.002) were receiving invasive mechanical ventilation; 31.0% of patients with ketosis vs 12.0% of patients without ketosis (p < 0.001) had digestive disorders; and 28.6% of patients with ketosis vs 13.5% of patients without ketosis (p<0.007) had acute respiratory distress syndrome.

Finally, the development of ketoacidosis in 3 diabetic subjects could be caused by poor control of their glycemic status, which is common during starvation or hypercatabolic conditions 49 , or by insulin deficiency and dehydration, particularly if the patients were treated with hypoglycemic drugs. 50 However, in the paper of Li J et al. there is no information about the treatment of diabetes in these patients. 45 In the absence of nutritional and diabetological data, it is quite difficult to hypothize a cause-effect relationship between ketosis and COVID-19 infection. The only plausible reason why patients were in ketosis at admission was the prolongation of physiological fasting conditions due to starvation, which is frequently observed in patients with acute respiratory distress syndrome (ARDS) with COVID-19, especially if subintensive or intensive care is required. 51 Apart from this report, no other study actually suggests a possible exacerbation of the clinical conditions of ARDS and COVID-19 patients due to a ketogenic diet, and a trial concerning the use of ketogenic diets in critical care patients is ongoing. 50 

For this purpose, a randomized controlled trial has been developed at IRCCS San Martino, Genoa, Italy, and submitted to the Regional Ethical Committee (KETOCOV-1 protocol 10517). The trial involves the treatment of patients with moderate severity COVID-19 in inpatient centers by using an EKD with natural Mediterranean food. The main endpoint is to try to prevent the progression towards CSS, ARDS and mortality/transfer to subintensive/intensive care units or to prevent the need for continuous positive airway pressure (CPAP) or intubation. Given these possible assumptions, an international, large, multicentric, nutritional protocol could be started in patients during the first days of COVID-19 symptoms, using a metabolic treatment for the prevention of a disease in which the therapeutic armamentarium is very limited.

During the exudative phase of ARDS, resident AM are activated and differentiate into the M1 phenotype. The activation of macrophages caused by infections induces a metabolic shift in M1 macrophages from OXPHOS to aerobic glycolysis (Warburg-like effect). [9] [10] The hyperactivation of M1 macrophages leads to the overproduction of proinflammatory cytokines (IFN-γ, TNF-α, and IL-1β). M1 macrophages secrete cytokines into the site of inflammation and recruit monocytes, which turn in, recruit M1 macrophages, by means of monocyte chemoattractant protein (MCP), neutrophils and platelets from circulating blood into the alveolar space, causing tissue damage and neutrophil extracellular traps (NETs), and monocyte-platelet aggregates, which could be responsible for DIC. 

A EKD (eucaloric ketogenic diet) could reduce glucose availability for aerobic glycolysis (Warburg-like effect) in M1 macrophages. The main target of this approach is to inhibit M1 phagocyte hyperactivation, which provokes the overproduction of proinflammatory cytokines (IFN -γ, TNF-α, and IL-1β), leading to excessive accrual of monocytes, neutrophils and platelets from the blood.

COVID-19: consider cytokine storm syndromes and immunosuppression

Coagulopathy Associated with COVID-19J

Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Obesity and SARS-CoV-2: a population to safeguard

Cellular adaptation to hypoxia through hypoxia inducible factors and beyond

Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus

Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells

Metabolic reprogramming in macrophages and dendritic cells in innate immunity

The Role of Macrophages in the Pathogenesis of ALI/ARDS

Neutrophils and the adult respiratory distress syndrome

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Broad Infiltration of Macrophages Leads to a Proinflammatory State in Streptozotocin-Induced Hyperglycemic Mice

Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure

The acute respiratory distress syndrome

Lactate as substrate for mitochondrial respiration in alveolar epithelial type II cells

Lactate is a natural suppressor of RLR signaling by targeting MAVS

Severe Acute Respiratory Syndrome Coronavirus Elicits a Weak Interferon Response Compared to Traditional Interferon-Inducing Viruses

TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKε supports the anabolic demands of dendritic cell activation

SARS-CoV-2 infected host cell proteomics reveal potent ial therapy targets

Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: A comprehensive review of the literature

Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma

Low-carbohydrate diet review: shifting the paradigm

Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets

Mitochondrial dysfunction and oxidative stress in neurodegenerative Diseases

Linking the metabolic state and mitochondrial DNA inchronic disease, health and aging

Stress hyperglycemia, inflammation, and cardiovascular events, Diabetes Care

Chronic hyperglycemia predisposes to exaggerated inflammatory response and leukocyte dysfunction in Akita mice

Eucaloric Ketogenic Diet Reduces Hypoglycemia and Inflammation in Mice with Endotoxemia

The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism

The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies

The _-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages

The role of HCA2 (GPR109A) in regulating macrophage function

Ketogenic diet activates protective γδ T cell responses against influenza virus infection

Feasibility of protein-sparing modified fast by tube (ProMoFasT) in obesity treatment: a phase II pilot trial on clinical safety and efficacy (appetite control, body composition, muscular strength, metabolic pattern, pulmonary function test)

Effects of Twenty Days of the Ketogenic Diet on Metabolic and Respiratory Parameters in Healthy Subjects

Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base

Glucose control in the ICU

High fat, low carbohydrate, enteral feeding lowers PaCO2 and reduces the period of ventilation in artificially ventilated patients

High fat, low carbohydrate, enteral feeding in patients weaning from the ventilator

Effect of low calorie intake on abnormal pulmonary physiology in patients with chronic hypercapneic respiratory failure

Glucose as a Major Antioxidant: When, What for and Why It Fails? Antioxidants 2020

Nutritional Ketosis and Mitohormesis: Potential Implications for Mitochondrial Function and Human Health

Very Low-Calorie Ketogenic Diet: A Safe and Effective Tool for Weight Loss in Patients with Obesity and Mild Kidney Failure

COVID-19 infection may cause ketosis and ketoacidosis

Adjustment to dietary energy availability: from starvation to overnutrition

Ketone body metabolism in lean male adults during short-term starvation, with particular reference to forearm muscle metabolism

Nutritional Ketosis for Weight Management and Reversal of Metabolic Syndrome

Adaptive reciprocity of lipid and glucose metabolism in human short-term starvation

Diabetic ketoacidosis in adults

ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection

Keto-diet for Intubated Critical Care

a. modulation of CSS by reducing metabolism of M1 macrophage phenotype by reducing glucose availability b. metabolic promotion of the anti-inflammatory M2 macrophage phenotype fueled by fatty acids c. reduced production of lactate associated with disinhibition of IFN I production 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.